Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

NCT05332561 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Early-stage Breast Cancer

Interventions

DRUG: Atezolizumab 1200 mg in 20 ML Injection
DRUG: Inavolisib
DRUG: Ipatasertib
DRUG: Olaparib
DRUG: Sacituzumab govitecan
DRUG: Trastuzumab/pertuzumab

Sponsor

German Cancer Research Center